- Home
- LIXT vs NXGL Comparison
LIXT vs NXGL Comparison
Compare LIXT & NXGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- NXGL
- Stock Information
- Founded
- LIXT 2005
- NXGL 1997
- Country
- LIXT United States
- NXGL United States
- Employees
- LIXT N/A
- NXGL N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- NXGL Medical/Dental Instruments
- Sector
- LIXT Health Care
- NXGL Health Care
- Exchange
- LIXT Nasdaq
- NXGL Nasdaq
- Market Cap
- LIXT 20.5M
- NXGL 18.7M
- IPO Year
- LIXT N/A
- NXGL 2021
- Fundamental
- Price
- LIXT $4.35
- NXGL $2.45
- Analyst Decision
- LIXT
- NXGL
- Analyst Count
- LIXT 0
- NXGL 0
- Target Price
- LIXT N/A
- NXGL N/A
- AVG Volume (30 Days)
- LIXT 129.2K
- NXGL 65.2K
- Earning Date
- LIXT 11-07-2025
- NXGL 11-10-2025
- Dividend Yield
- LIXT N/A
- NXGL N/A
- EPS Growth
- LIXT N/A
- NXGL N/A
- EPS
- LIXT N/A
- NXGL N/A
- Revenue
- LIXT N/A
- NXGL $11,672,000.00
- Revenue This Year
- LIXT N/A
- NXGL $46.60
- Revenue Next Year
- LIXT N/A
- NXGL $47.96
- P/E Ratio
- LIXT N/A
- NXGL N/A
- Revenue Growth
- LIXT N/A
- NXGL 133.02
- 52 Week Low
- LIXT $0.64
- NXGL $2.10
- 52 Week High
- LIXT $6.26
- NXGL $5.10
- Technical
- Relative Strength Index (RSI)
- LIXT 45.71
- NXGL 44.97
- Support Level
- LIXT $4.05
- NXGL $2.45
- Resistance Level
- LIXT $4.42
- NXGL $2.71
- Average True Range (ATR)
- LIXT 0.40
- NXGL 0.18
- MACD
- LIXT -0.04
- NXGL -0.01
- Stochastic Oscillator
- LIXT 41.51
- NXGL 24.53
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.